This study provides direct experimental evidence that tau co-pathology contributes to disease progression in synucleinopathies, underscoring the therapeutic potential of targeting pathological tau to mitigate neurodegeneration in PD, DLB, and related disorders. Here, MAPT is linked to synucleinopathy.